digitoxigenin-3-sulfate | 1071173-30-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: digitoxigenin-3-sulfate
• 英文别名: [(3S,5R,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate
• CAS: 1071173-30-2
• 化学式: C₂₃H₃₄O₆S
• 分子量: 438.585
• InChiKey: OGPFFGTXNXQWCE-RDIILWCNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  30
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  98.3
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• EP0647133A4
  申请人：——

  公开号：EP0647133A4

  公开（公告）日：1997-10-29
• COMPOSITIONS AND METHODS FOR ENHANCED DRUG DELIVERY
  申请人：AFFYMAX TECHNOLOGIES N.V.

  公开号：EP0647133A1

  公开（公告）日：1995-04-12
• Chiral separation, characterization and biological action of optically active isomers of digoxin
  申请人：Somberg Charin John

  公开号：US20060069043A1

  公开（公告）日：2006-03-30

  Disclosed herein is the method for separation of enantiomers or isomers of digoxin. These isomers are to be used in the treatment of heart failure without adverse or unneeded cardiac actions in humans. Additionally what is claimed is an isolate with less or no cardiac contractile effect but with AV node slowing such that the composition would be an effective therapy for the control of the ventricular response in atrial fibrillation. Also disclosed are methods for assaying these isomeric compounds present in biological fluids to enable the separation of pharmacologic actions.
• US5607691A
  申请人：——

  公开号：US5607691A

  公开（公告）日：1997-03-04
• [EN] COMPOSITIONS AND METHODS FOR ENHANCED DRUG DELIVERY<br/>[FR] COMPOSITIONS ET PROCEDES DESTINES A AMELIORER LA LIBERATION ET L'ACHEMINEMENT DE MEDICAMENTS
  申请人：AFFYMAX TECHNOLOGIES N.V.

  公开号：WO1993025197A1

  公开（公告）日：1993-12-23

  (EN) The present invention relates to methods of delivering pharmaceutical agents across membranes, including the skin layer or mucosal membranes of a patient. A pharmaceutical agent is covalently bonded to a chemical modifier, via a physiologically cleavable bond, such that the membrane transport and delivery of the agent is enhanced.(FR) La présente invention se rapporte à des procédés de libération d'acheminement d'agents pharmaceutiques à travers des membranes, y compris l'épiderme ou les muqueuses d'un patient. Un agent pharmaceutique est lié de manière covalente à un modificateur chimique, via une liaison physiologiquement clivable, de telle façon que le transport et la libération de l'agent par la membrane soient améliorés.